Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. 1992

E D Kreuser, and D Felsenberg, and C Behles, and H Seibt-Jung, and M Mielcarek, and V Diehl, and E Dahmen, and E Thiel
Department of Internal Medicine (Hematology/Oncology), Free University of Berlin, Germany.

Only limited data is currently available on long-term gonadal toxicity and its impact on bone mineralization in men and women treated for Hodgkin's disease. The present study was therefore conducted to evaluate gonadal toxicity and bone loss in 49 patients with Hodgkin's disease 2-10 (median 5.37) years after chemotherapy. Most patients were treated with the COPP/ABVD regimen +/- irradiation according to the protocols of the German Hodgkin Study Group. Blood samples were tested for gonadotropins (FSH, LH), gonadal steroids, parathyroid hormone, osteocalcin, and calcitonin. Bone mineral density was measured using single- and dual-energy quantitative computed tomography as well as single-photon absorptiometry. FSH serum levels were significantly increased in 21/27 (80%) men demonstrating germ-cell aplasia. 13/15 (86%) men showed azoospermia after the COPP/ABVD regimen. In contrast, testosterone levels were within normal limits in all men tested, suggesting normal Leydig-cell function. 17/22 (77%) women exhibited increased FSH and LH levels, indicating premature ovarian failure. Women with therapy-induced ovarian failure had a significantly lower trabecular (98 +/- 34) and cortical (292 +/- 48 mg/cm3) spinal bone density than those with normal ovarian function. Men showed no evidence of bone loss after therapy. These data suggest severe gonadal toxicity in both men and women treated with the COPP/ABVD regimen. In female patients, drug-induced ovarian failure has a significant impact on bone mineralization.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010053 Ovary The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE. Ovaries
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011344 Procarbazine An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. Matulane,Natulan,Procarbazine Hydrochloride,Procarbazine Monohydrobromide,Procarbazine Monohydrochloride,Hydrochloride, Procarbazine,Monohydrobromide, Procarbazine,Monohydrochloride, Procarbazine
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D003037 Cobalt Radioisotopes Unstable isotopes of cobalt that decay or disintegrate emitting radiation. Co atoms with atomic weights of 54-64, except 59, are radioactive cobalt isotopes. Radioisotopes, Cobalt
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271

Related Publications

E D Kreuser, and D Felsenberg, and C Behles, and H Seibt-Jung, and M Mielcarek, and V Diehl, and E Dahmen, and E Thiel
August 1997, American journal of clinical oncology,
E D Kreuser, and D Felsenberg, and C Behles, and H Seibt-Jung, and M Mielcarek, and V Diehl, and E Dahmen, and E Thiel
January 1987, Journal of cancer research and clinical oncology,
E D Kreuser, and D Felsenberg, and C Behles, and H Seibt-Jung, and M Mielcarek, and V Diehl, and E Dahmen, and E Thiel
June 2003, The New England journal of medicine,
E D Kreuser, and D Felsenberg, and C Behles, and H Seibt-Jung, and M Mielcarek, and V Diehl, and E Dahmen, and E Thiel
January 1997, Neoplasma,
E D Kreuser, and D Felsenberg, and C Behles, and H Seibt-Jung, and M Mielcarek, and V Diehl, and E Dahmen, and E Thiel
August 1996, Medical and pediatric oncology,
E D Kreuser, and D Felsenberg, and C Behles, and H Seibt-Jung, and M Mielcarek, and V Diehl, and E Dahmen, and E Thiel
December 1982, British medical journal (Clinical research ed.),
E D Kreuser, and D Felsenberg, and C Behles, and H Seibt-Jung, and M Mielcarek, and V Diehl, and E Dahmen, and E Thiel
May 1985, European journal of cancer & clinical oncology,
E D Kreuser, and D Felsenberg, and C Behles, and H Seibt-Jung, and M Mielcarek, and V Diehl, and E Dahmen, and E Thiel
June 1986, Annals of internal medicine,
E D Kreuser, and D Felsenberg, and C Behles, and H Seibt-Jung, and M Mielcarek, and V Diehl, and E Dahmen, and E Thiel
April 1987, International journal of radiation oncology, biology, physics,
E D Kreuser, and D Felsenberg, and C Behles, and H Seibt-Jung, and M Mielcarek, and V Diehl, and E Dahmen, and E Thiel
March 1982, Cancer treatment reviews,
Copied contents to your clipboard!